2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
5
Breast Neoplasms
5
Head and Neck Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Oropharyngeal Neoplasms
2
Neuroblastoma
2
Neoplasm Metastasis
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenocarcinoma
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Squamous Cell Cancer of Head and Neck (SCCHN)
1
Skin Neoplasms
1
Sarcoma, Clear Cell
1
Rhabdoid Tumor
1
Recurrence
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Radiotherapy, Image-Guided
×
Clear all
NCT05328505
2026-03-24
MIDAS-Prostate
University Health Network, Toronto
Phase NA
Recruiting
80 enrolled